First epidemiological study: Omicron with significant immune escape
- FDA Approves Expanded Injectable Treatment Formula for Smallpox-Monkeypox
- UK and Netherlands follow Belgium to implement “monkeypox quarantine”
- European EMA removes about 100 generic drugs
- EU approves AstraZeneca’s COVID-19 vaccine as booster shot
- First injection of cancer-killing oncolytic virus into human patient
- First monkeypox quarantine order: Belgium requires to self-isolate for 21 days
First epidemiological study: Omicron with significant immune escape
- Unexplained acute hepatitis in children may be related to COVID superantigens
- How long can the patient live after heart stent surgery?
- Keytruda: The 5-year survival rate for advanced lung cancer doubled!
- Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
- Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
First epidemiological study: Omicron with significant immune escape.
[Heavyweight] The first epidemiological study of Omicron causing superinfection, showing that the phenomenon of immune escape is more significant.
On December 2, 2021, Pulliam of Stellenbosch University in South Africa and others uploaded the first research paper on Omicron mutant strains on bioRxiv, the title is “Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa” (The increased risk of SARS-CoV-2 superinfection in South Africa is related to the Omicron mutant ).
This blockbuster study describes the epidemiology of Omicron’s repeated infections .
In a cohort of 2,796,982 patients previously infected with SARS-CoV-2, the study found 35,670 repeat infections before November 27.
Studies have found that, compared with wild-type strains, Beta and Delta mutant strains increase the risk of initial infection (first infection) in the population , but do not increase the risk of reinfection, that is to say, the immunity formed after initial infection is against reinfection. Still valid. Omicron is contrary to the prevalence of the above two mutant strains.
The study found that Omicron did not increase the risk of initial infection in the population, and even the risk of initial infection in the population was reduced; but it increased the risk of reinfection .
In the second and third peaks dominated by Beta and Delta mutant strains, the hazard ratios of repeated infections were 0.75 and 0.71, respectively. In South Africa’s recent fourth peak led by Omicron, the hazard ratio of repeated infections rose to 2.39 .
In other words, the immune escape phenomenon of Omicron may be more significant .
Therefore, it is critical to continue to monitor its epidemic and conduct serological research.
references:
https://www.medrxiv.org/content/10.1101/2021.11.11.21266068v2.full.pdf
First epidemiological study: Omicron with significant immune escape
(source:internet, reference only)
Disclaimer of medicaltrend.org
